Opioid

Shares of Adamis Pharmaceuticals Corp (NASDAQ: ADMP) soared higher by 60 percent early Monday morning in reaction to a new partnership with Novartis AG (ADR) (NYSE: NVS). What Happened Adamis, a specialty biopharmaceutical company that focuses on treatments for respiratory diseases and...

President Donald Trump in March said he was considering suing drug companies fueling the opioid crisis — and Congress will allocate $6 billion in new funding over the next two years to advance the fight. The strategy, coupled with other policies, could bode well for Recro Pharma Inc (...

Insys Therapeutics Inc (NASDAQ: INSY), a pharmaceutical company that focuses on a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients called Subsys, reported its fourth quarter results Thursday which prompted Piper Jaffray to downgrade the stock. The Analyst...

Shares of Insys Therapeutics Inc (NASDAQ: INSY) plummeted as low as $4.10 Tuesday morning as the company faces a notable legal battle concerning its founder John Kapoor. Kapoor resigned from Insys' board of directors over the weekend after he was arrested last week. The executive is said to...

Opiant Pharmaceuticals Inc (NASDAQ: OPNT) spiked 46 percent Thursday when President Donald Trump declared a crackdown on opioid abuse. “We’re going to be spending lots of money on coming up with a non-addictive solutions,” Trump said during a press conference. The company develops...

President Donald Trump catalyzed a selloff in opioid-exposed stocks Thursday as he declared the national epidemic a public health emergency and renewed the government’s crackdown on fentanyl. “I will be pushing the concept of non addictive painkillers very, very hard,” Trump said...

On the same day President Donald Trump was expected to declare the national opioid epidemic a public health emergency, a Boston Federal Court charged John Kapoor, former CEO and chairman of the opioid producing Insys Therapeutics Inc (NASDAQ: INSY), along with six other executives with a...

Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) peaked north of $250 per share in 2015, but by 2017 they dropped to a single digit. Needless to say, this represented a challenging time for the company.   But since bottoming at $8.31 per share this year, the company has made "great...

The U.S. Food and Drug Administration's quest to address the growing opioid crisis is hurting many pharmaceutical companies, including Endo International plc - Ordinary Shares (NASDAQ: ENDP), presenting an opportunity for companies like Alkermes Plc (NASDAQ: ALKS), which makes treatments for opioid...

Shares of Endo International plc - Ordinary Shares (NASDAQ: ENDP) were trading lower by more than 10 percent Friday morning in reaction to the U.S. Food and Drug Administration's request for the company to withdraw from the market its opioid painkiller called Opana ER. Stifel's Annabel Samimy felt...

Insys Therapeutics Inc (NASDAQ: INSY) is a commercial-stage specialty pharmaceutical company whose product Subsys is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients On Thursday, shares of Insys fell more than 3 percent after the Department of Justice...